Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: benoxaprofen | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 340 | 0.74 |
| pathways Reactome | 6 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6069
Sealed predictions
- ALOX12 in dopamine neurons, braak-0.42 (p 0.255) → +0.24 (p 0.533)receipt 6075
Swarm cases
receipt 6075: ALOX12 in dopamine neurons, braak
- power
- full sample -0.18 (p 0.487, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.515, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.12 (p 0.627, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.08, sign flips 0; without severely affected donors -0.18 (p 0.487, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALOX12 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts